Brief: Bone Therapeutics Eyes EUR 15-16 Mln FY Net Cash Burn

Biosenic SA

30/10/2020 06:19

Oct 30 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * REG-BONE THERAPEUTICS PROVIDES THIRD QUARTER 2020 BUSINESS UPDATE
    * NET CASH AT END OF SEPTEMBER 2020 AMOUNTED TO EUR 5.6 MILLION.
    * NET CASH BURN FOR FULL YEAR 2020 IS EXPECTED TO BE APPROXIMATELY EUR 15-16 MILLION.
    * EXPECTS TO COMPLETE PATIENT ENROLLMENT IN PHASE III JTA-004 STUDY BEFORE YEAR-END.
    * TOPLINE RESULTS ARE ANTICIPATED ON 3-MONTH PRIMARY ENDPOINT AND 6-MONTH FOLLOW-UP PERIOD
IN
SECOND HALF OF 2021.
    * EXPECTS TO INITIATE CLINICAL TRIAL ACTIVITIES AND PATIENT RECRUITMENTS FOR ALLOB PHASE IIB
STUDY
IN PATIENTS WITH DIFFICULT TIBIAL FRACTURES IN EUROPEAN CLINICAL CENTERS BEFORE END OF YEAR
    * AS EFFECTS OF PANDEMIC CONTINUE TO EVOLVE GLOBALLY, IT IS POSSIBLE THAT BOTH STUDIES MAY
ENCOUNTER A DELAY COMPARED TO ANTICIPATED SCHEDULE
    * DECIDED TO TERMINATE CONVERTIBLE BOND PROGRAM ISSUED IN APRIL 2020.
    * INTENDS TO PREPARE A FUNDRAISE IN Q4 OF 2020
    * IN NOVEMBER, BONE THERAPEUTICS PLANS TO INITIATE DISCUSSIONS WITH US FDA  IN PREPARATION
FOR
NEXT STEPS IN CLINICAL DEVELOPMENT OF JTA-004 IN US
    * ANTICIPATES HAVING SUFFICIENT CASH TO CARRY OUT ITS BUSINESS OBJECTIVES UNTIL EARLY Q3
2021

Source text for Eikon:  ID:nGNE4fbl48 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))